Enterprise Value
2.513B
Cash
783M
Avg Qtr Burn
-147M
Short % of Float
13.92%
Insider Ownership
6.89%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Adagrasib (MRTX849) KRAS G12C Inhibitor Details Cancer, Lung cancer, Solid tumor/s, Colorectal cancer , Non-small cell lung carcinoma | Approved Quarterly sales | |
Sitravatinib (TAM inhibitor) plus nivolumab (OPDIVO®) Details Non-small cell lung carcinoma | Phase 3 Data readout | |
Adagrasib (MRTX849) + cetuximab Details Solid tumor/s, Colorectal cancer , Cancer | Phase 3 Data readout | |
KRAZATI (Adagrasib) (MRTX849) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Data readout | |
Adagrasib (MRTX849) + Pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Initiation | |
MRTX0902 (Potent SOS1 inhibitor) +adagrasib Details Solid tumor/s | Phase 1/2 Data readout | |
MRTX1133 Details Solid tumor/s, Cancer, Colorectal cancer , Pancreatic cancer, Lung cancer | Phase 1/2 Data readout | |
Adagrasib (MRTX849) KRAS G12C Inhibitor + VS-6766 in KRASG12C-mutant Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 1/2 Initiation | |
MRTX1719 (PRMT5 inhibitor) Details Solid tumor/s, Cancer | Phase 1/2 Initiation | |
Sitravatinib plus tislelizumab Details Platinum-resistant ovarian cancer | Phase 1b Interim update |